Friend or Foe? The Role of Regulatory Relief in Drug Shortages
This article was originally published in The Gold Sheet
FDA’s Janet Woodcock argues that strong enforcement prevents drug shortages, dismissing allegations that crackdown under Hamburg triggered shortage crisis. There is more agreement, however, on the role of other factors such as group purchasing organizations, or GPOs, in the crisis.
You may also be interested in...
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
The number of drug GMP warning letters issued by FDA continued to climb in fiscal year 2011, with supply chain and sterility assurance issues dominating the agency’s attention. FDA is requesting a budget increase in FY 2013 to expand its inspectional presence abroad to better meet global supply chain threats, and agency officials are saying that failure to monitor contract manufacturers is a major problem shown in recent warning letters, but that failure to investigate out-of-specification results is still the No. 1 finding.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.